journal
MENU ▼
Read by QxMD icon Read
search

Drugs of Today

journal
https://read.qxmd.com/read/30740611/the-year-s-new-drugs-and-biologics-2018-part-i
#1
A I Graul, P Pina, E Cruces, M Stringer
Sixty-four new drugs and biologics reached their first global markets in 2018, the greatest number in at least a decade. In addition, 19 important new line extensions (new indications, new combinations or new formulations of previously marketed drugs) were introduced over the course of 2018. Twenty-three other new products and new line extensions were approved but not launched before December 31. As has been the trend in recent years, oncology was the most active therapeutic area in terms of new launches, with cancer drugs accounting for 25% of all novel drugs and biologics introduced worldwide last year...
January 2019: Drugs of Today
https://read.qxmd.com/read/30740610/ibalizumab-for-the-treatment-of-multidrug-resistant-hiv-1-infection
#2
S A Rizza, R Bhatia, J Zeuli, Z Temesgen
Ibalizumab, a humanized monoclonal antibody to CD4, was recently approved by the United States Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Ibalizumab is the first in a new class of antiretroviral drugs designated as post-attachment inhibitors. It exerts its antiviral effect by noncompetitive binding of CD4, thereby blocking conformational changes in the CD4-gp120 complex that are essential for viral entry...
January 2019: Drugs of Today
https://read.qxmd.com/read/30740609/condoliase-for-treatment-of-lumbar-disc-herniation
#3
Y Matsuyama, K Chiba
Lumbar disc herniation (LDH) is generally treated with a conservative therapy, and surgery is the only therapeutic option currently available for patients unresponsive to the conservative therapy. In the 1980s, chemonucleolysis with chymopapain, a protease, was widely used as the intermediate treatment between conservative therapy and surgical therapy in the Western countries. However, since chymopapain was withdrawn from the market in 2002 for non-scientific commercial reasons, chemonucleolysis has not been a therapeutic option for LDH...
January 2019: Drugs of Today
https://read.qxmd.com/read/30740608/abiraterone-acetate-to-treat-metastatic-castration-resistant-prostate-cancer-in-combination-with-prednisone
#4
C Duarte, A Jimeno, E R Kessler
Prostate cancer is one of the most common cancers in the United States, with an estimated incidence of 164,690 cases, accounting for 9.5% of all new cancer diagnoses. The mainstay of therapy for metastatic prostate cancer involves suppressing testosterone production through androgen deprivation therapy. However, nearly all patients on androgen deprivation therapy will develop resistance to hormone therapy. An improved understanding of the biology of castration resistance has allowed for the development of novel inhibitors of the androgen axis...
January 2019: Drugs of Today
https://read.qxmd.com/read/30596393/the-financial-times-global-pharmaceutical-and-biotechnology-conference-embracing-disruption-for-a-new-era-in-health-november-5-6-2018-london-uk
#5
A Kibble
The Financial Times (FT) Global Healthcare conference brought together top-level executives and leaders in global healthcare and technology around a fascinating and thought-provoking agenda. Consisting of a wide range of expert panel discussions chaired by the FT and Deloitte's specialist editors, as well as a series of keynote CEO interviews, the conference took an in-depth and nuanced view of the forces of disruption colliding in healthcare at the moment. Gains in R+D are implicit, but beyond this, technology and data disruption can potentially transform all aspects of healthcare through patient-centered care, the march of big data, advanced analytics and the entrance of new players in the market such as technology firms and app providers...
December 2018: Drugs of Today
https://read.qxmd.com/read/30596392/%C3%AE-lactamase-inhibitor-peptides-as-the-new-strategies-to-overcome-bacterial-resistance
#6
O N Silva, O L Franco, W F Porto
Bacterial resistance has become a problem of great concern all over the world. Gram-negative bacteria, including the Enterobacteriaceae family and Pseudomonas and Acinetobacter species, are among the leading causes of healthcare-associated infections. The rate of antibiotic resistance among these pathogens has increased dramatically in recent years, reaching a pandemic scale. The most common mechanism of resistance described for Gram-negative bacteria consists of beta-lactamase production. These enzymes hydrolyze beta-lactam antibiotics, which are among the most commonly used antimicrobial agents...
December 2018: Drugs of Today
https://read.qxmd.com/read/30596391/volanesorsen-for-treatment-of-patients-with-familial-chylomicronemia-syndrome
#7
B A Warden, P B Duell
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder typically caused by mutations in genes for lipoprotein lipase (LPL), apolipoprotein C-II (Apo-CII), apolipoprotein A-V (Apo-AV), lipase maturation factor 1 (LMF1) and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1). FCS is associated with severe morbidity that includes recurrent pancreatitis and other problems. Effective treatment to reliably prevent complications has been unavailable, so there is a quest to identify novel interventions to achieve sustained triglyceride lowering and prevention of pancreatitis...
December 2018: Drugs of Today
https://read.qxmd.com/read/30596390/lumateperone-a-new-treatment-approach-for-neuropsychiatric-disorders
#8
B Kumar, A Kuhad, A Kuhad
Lumateperone tosylate (ITI-007 tosylate, ITI-722) is a first-in-class investigational drug which acts syn-ergistically through multiple systems (serotonergic, dopaminergic and glutamatergic), thus representing a unique approach for the therapeutic management of a range of neuropsychiatric disorders. It possesses a potent antagonistic activity at 5-hydroxytryptamine (serotonin) 2A (5-HT2A) receptors and also binds to dopamine (D1, D2) receptors with partial agonism at presynaptic D2 receptors and postsynaptic antagonism...
December 2018: Drugs of Today
https://read.qxmd.com/read/30539168/new-therapies-for-anaplastic-thyroid-cancer
#9
V R Agrawal, J Hreno, T Patil, D W Bowles
Anaplastic thyroid cancer is a rare but extremely aggressive type of thyroid cancer. Treatment typically consists of surgery, external beam radiotherapy and cytotoxic chemotherapy. However, available literature suggests only modest survival benefit for cytotoxic chemotherapy. Recent advances have suggested the combination of BRAF and MEK inhibition may have a profound and durable effect on patients with BRAFV600E-mutated anaplastic thyroid cancer, with a response rate of 69%. Other systemic treatments, including immunotherapies, have also shown promising but more limited results...
November 2018: Drugs of Today
https://read.qxmd.com/read/30539167/an-update-on-sargramostim-for-treatment-of-acute-radiation-syndrome
#10
V K Singh, T M Seed
The potential use by terrorists of an improvised nuclear device, a radiological dispersal device, or an unintended nuclear/radiological accident in heavily populated areas is a national security threat of major consequences. Although this type of security threat is considered to be low-risk, it would have a devastating impact. Health issues would be a major concern; medical care would be necessary for all those who received considerable radiation exposure (> 1 Gy) leading to hematopoietic acute radiation syndrome (ARS)...
November 2018: Drugs of Today
https://read.qxmd.com/read/30539166/estradiol-vaginal-inserts-imvexxy-effective-in-genitourinary-syndrome-of-menopause-without-increasing-systemic-estrogen-levels
#11
D M Paton
Many women suffer from the genitourinary syndrome of the menopause (GSM), in particular pathological changes that occur in the vagina due to the reduction in their production of estrogens. TherapeuticsMD has developed Imvexxy, small softgel capsules that contain solubilized estradiol and that are inserted vaginally by women twice a week, every 3 to 4 days. These vaginal inserts have been found to readily supply estradiol to the vagina and to result in significant improvement in the GSM signs and symptoms these women had been experiencing...
November 2018: Drugs of Today
https://read.qxmd.com/read/30539165/delafloxacin-meglumine-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-absssi
#12
G Kaul, E Kapoor, A Dasgupta, S Chopra
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials. Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes...
November 2018: Drugs of Today
https://read.qxmd.com/read/30539164/avatrombopag-maleate-for-the-treatment-of-periprocedural-thrombocytopenia-in-patients-with-chronic-liver-disease
#13
H Al-Samkari
Avatrombopag maleate (Doptelet; Dova Pharmaceuticals) is an oral, small-molecule second-generation thrombopoietin (TPO) receptor agonist under development for the treatment of thrombocytopenia. Recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease on the basis of the results of two phase III trials, it is currently under investigation for treatment of immune thrombocytopenia (two randomized trials demonstrating efficacy have already been completed), chemotherapy-induced thrombocytopenia and perioperative thrombocytopenia in patients undergoing major surgical procedures...
November 2018: Drugs of Today
https://read.qxmd.com/read/30398483/life-sciences-licensing-deals-in-the-second-quarter-of-2018-updates-and-trends
#14
P D'Souza
During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers and acquisitions) with a total disclosed deal value of USD 19.5 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 964 and USD 35.6 billion in the first quarter and 1,104 and USD 13.6 billion in the second quarter of 2017. Total deal value in the second quarter did not quite reach the peak of 2014 (paced by Novartis' USD 16 billion purchase of GlaxoSmithKline's oncology portfolio) but eclipsed the previous quarter primarily due to Allogene's USD 2...
October 2018: Drugs of Today
https://read.qxmd.com/read/30398482/an-update-of-treatments-of-hepatocellular-carcinoma-in-patients-refractory-to-sorafenib
#15
L Ielasi, V Sansone, A Granito, F Benevento, S De Lorenzo, F Tovoli
Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic treatments for HCC have been scarce. In particular, sorafenib was the only registered drug for the treatment of unresectable HCC until 2017. Last year, regorafenib was approved by the global regulatory agencies as second-line therapy. Since then, further randomized, controlled trials have been successful in this patient population. This paper deals with the most recent data concerning cabozantinib and ramucirumab, the two drugs that have recently demonstrated efficacy in phase III, randomized, controlled trials in HCC patients who failed previous treatment with sorafenib...
October 2018: Drugs of Today
https://read.qxmd.com/read/30398481/sodium-zirconium-cyclosilicate-a-new-potassium-binder-for-the-treatment-of-hyperkalemia
#16
A Cases, J L Gorriz
Hyperkalemia is one of the most common electrolyte disturbances, especially among some groups of patients, such as in those with chronic kidney disease, diabetes or heart failure. Hyperkalemia has been associated with increased risks of mortality, arrhythmias, hospitalization and costs, as well as the need to down titrate/discontinue renin-angiotensin-aldosterone system inhibitors (RAASIs), despite their well-known cardiovascular and nephroprotective benefits. Current potassium binders have limitations (slow onset of action, limited selectivity for potassium binding, risk of drug interactions or gastrointestinal intolerance)...
October 2018: Drugs of Today
https://read.qxmd.com/read/30398480/emicizumab-for-routine-prophylaxis-to-prevent-bleeding-episodes-in-patients-with-hemophilia-a
#17
M Díaz-Ricart, I M Isola, G Escolar
Hemophilia A is an X-linked bleeding disorder caused by defects in the gene encoding factor VIII (FVIII). Routine prophylaxis with exogenous FVIII requires frequent intravenous injections. One of the most challenging issues in the treatment of hemophilia A is the development of alloantibodies against infused FVIII. Presence of inhibitors results in an ineffective factor replacement therapy and increases the risk of morbidity and mortality in these patients. Therefore, there is growing interest in the development of new strategies for the prophylaxis and prevention of bleeding in patients with hemophilia to circumvent these drawbacks...
October 2018: Drugs of Today
https://read.qxmd.com/read/30398479/apalutamide-for-the-treatment-of-patients-with-castration-resistant-prostate-cancer
#18
R Hauke
Patients with recurrent, nonmetastatic prostate cancer after curative intent therapy can experience a heterogeneous clinical course ranging from indolent disease that can be observed for years to a rapidly progressive disease that is metastatic in a relatively short time. Patients with short prostate-specific antigen (PSA) doubling times are at risk for early development of metastatic disease and are frequently placed on androgen deprivation therapy. Although castration-resistant disease inevitably occurs in these patients, most therapies for castration-resistant disease have shown benefit in the metastatic setting...
October 2018: Drugs of Today
https://read.qxmd.com/read/30303496/renal-complications-of-cancer-therapies
#19
REVIEW
M Schanz, S Schricker, F Pfister, M D Alscher, M Kimmel
Cancer patients often exhibit preexisting renal impairment and are simultaneously at risk for developing further kidney injury due to direct or indirect complications of oncological therapies. The nature of kidney injury is highly dependent on the therapy regimen used, and the spectrum of possible kidney stressors has widened as a result of the development of new therapeutic modalities such as molecular therapy or immunotherapy. Indirect renal complications are often due to volume depletion or other therapy-related side effects...
September 2018: Drugs of Today
https://read.qxmd.com/read/30303495/cardiovascular-effects-of-antidiabetic-drugs
#20
A M Sørensen, M B Christensen
Type 2 diabetes mellitus is a common and severe chronic metabolic disease, which confers increased risk of cardiovascular disease and mortality. During the last decade a large number of new drugs within the classes dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP-4Is), glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT-2) inhibitors (SGLT-2Is) have been developed and tested in nine large-scale cardiovascular outcome trials (CVOTs). Here we review the evidence behind antihyperglycemic treatment of patients with type 2 diabetes with a particular focus on compiling and summarizing the evidence of hard clinical endpoints stemming from these large CVOTs...
September 2018: Drugs of Today
journal
journal
40337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"